Companies in #Cell Therapy

Clinical-stage cell therapy company developing next-generation CAR-T cell therapies for solid tumors.

Clinical-stage cell therapy company developing allogeneic, off-the-shelf T-cell immunotherapies for EBV-driven cancers and autoimmune diseases, including tab-cel (tabelecleucel) and next-generation CAR-T programs.

Clinical-stage biotech developing CAR-T cell therapies for pediatric brain tumors in the CNS. Spinout from Seattle Children's Hospital.

Capricor Therapeutics (NASDAQ: CAPR) is a cell therapy company headquartered in Beverly Hills, California, USA.

CareDx, Inc. is a molecular diagnostics company specializing in transplant surveillance, specialty oncology, and cell therapy testing. The company's AlloSure Kidney donor-derived cell-free DNA test is the leading non-invasive transplant monitoring assay in U.S. clinical use, complemented by AlloMap Heart for heart transplant recipients and HeartCare for combined heart transplant surveillance. Following the July 2026 close of the Naveris acquisition (adding the Medicare-covered NavDx MRD blood test for HPV-positive head-and-neck and anal cancers) and the $171.2M divestiture of its global Lab Products business to Eurobio Scientific, CareDx is repositioned as a focused U.S. precision-medicine testing and digital-patient-solutions company.

Fate Therapeutics is a clinical-stage biopharmaceutical company pioneering off-the-shelf NK and T-cell cancer immunotherapies derived from induced pluripotent stem cells (iPSCs). Its pipeline includes FT596 (CD19 CAR-NK), FT819 (CD19 CAR-T), and FT522 (CD19 + IL-15 CAR-NK) in hematologic malignancies and autoimmune disease.

Gilead Sciences (NASDAQ: GILD) is a Foster City, California-based biopharmaceutical company with leadership in HIV (Biktarvy, Descovy), viral hepatitis (Sovaldi, Harvoni, Epclusa), and a growing oncology franchise (Trodelvy, Yescarta, Tecartus).

Chinese cell therapy company developing BCMA-targeted CAR-T therapies, led by equecabtagene autoleucel (CT103A) for relapsed/refractory multiple myeloma, with an in vivo CAR-T pipeline.

New cell therapy licensing company founded by Ying Huang (former Legend Biotech CMO). Focused on licensing Asian cell therapy assets into Western markets with a $250M target raise.

Legend Biotech is a global clinical-stage biopharmaceutical company pioneering the development of chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and solid tumors. Its lead product, CARVYKTI® (ciltacabtagene autoleucel), is approved for relapsed/refractory multiple myeloma and is co-developed with Johnson & Johnson.

Persista Bio is a preclinical biotherapeutics company developing the O2Line oxygenated long-term cell implant system, designed to regulate blood sugar automatically for people with Type 1 diabetes without immunosuppression or daily injections, pumps or finger sticks. The company licenses foundational encapsulation technology from Cornell University and enabling oxygenation technology from Giner.

Commercial-stage biopharmaceutical company developing gene and cell therapies for difficult-to-treat diseases, with a focus on immuno-oncology and precision medicine; its AdenoVerse immunotherapeutic platform received FDA platform technology designation in September 2026.

Sail Biomedicines is a Flagship Pioneering-backed in vivo CAR-T biotech engineering mRNA-encoded therapeutics to treat autoimmune disease and cancer. The company is developing programmable medicines that instruct the body to produce its own therapeutic proteins inside target cells.

Senti Biosciences Holdings, Inc. is a clinical-stage synthetic biology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform and Regulator Dial technology platform. The company's lead clinical asset, SENTI-202, was a logic-gated CAR-NK cell therapy for relapsed/refractory AML that received RMAT designation from FDA. On July 15, 2026 the company announced a strategic transaction spinning off its Gene-Circuit-enabled pipeline (including SENTI-202) into a newly formed private company controlled by Celadon Partners (Senti's largest investor) in exchange for a contingent value right worth up to $60M in milestone payments over seven years. Post-transaction, the retained company plans to focus on early-stage Regulator Dial programs including a controllable gene therapy for Rett Syndrome and armored tumor-infiltrating lymphocytes (TILs) for solid tumors.

Clinical-stage regenerative medicine company developing an allogeneic, off-the-shelf Small Mobile Stem (SMS) cell platform derived from adult blood, led by an inhaled SMS cell therapy program for COPD.